- Policy
- The government will begin to establish an Asian vaccine fund
- by Lee, Jeong-Hwan Mar 15, 2022 05:58am
- The government will review the need for joint vaccine purchase funds in Asia and start working on creating grounds for establishment. The move is aimed at preventing repeated cases of global difficulties in supplying vaccines with COVID-19 Pandemic and bridging the gap in accessibility to public vaccines and biopharmaceuticals by country.
- Policy
- RET mutant target anticancer drug has been approved
- by Lee, Tak-Sun Mar 15, 2022 05:57am
- For the first time in Korea, a new anticancer drug targeting a REarranged during Transfection (RET) mutation has been approved. RET is a phosphorylation enzyme that can cause cancer and is known to promote the proliferation of cancer cells when mutated or combined with other genes. The MFDS approved "Retevmo Capsule 40·80mg (Selpercatinib
- Policy
- Yoon Seok-yeol was elected president
- by Lee, Jeong-Hwan Mar 15, 2022 05:57am
- Attention is focusing on the pledge to establish a global vaccine hub and quickly register health insurance for severe treatments. In the 20th presidential election, Yoon Seok-yeol, the power of the people, was confirmed to win the election, beating Lee Jae-myung of the Democratic Party of Korea. Candidate Yoon Seok-yeol won 48.56% (16,394,81
- Policy
- Yoon Seok-yeol expands R&D for telemedicine & bio
- by Lee, Jeong-Hwan Mar 14, 2022 05:51am
- After the inauguration of the Yoon Seok-yeol administration, legal experts analyzed that the biohealth industry policy paradigm will shift, such as expanding digital healthcare and strengthening government R&D support in advanced medical fields of vaccines and treatments. It is predicted that the biohealth sector will be transformed compar
- Policy
- P3T for Sarepta’s DMD treatment approved in Korea
- by Lee, Hye-Kyung Mar 14, 2022 05:51am
- A Phase III trial for the Duchenne muscular dystrophy treatment 'SRP-4045(casimersen)’ and 'SRP-4053 (golodirsen)' will be conducted in Korea. The Ministry of Food and Drug Safety has recently approved Ppdd Velllovement Pte Ltd’s application for the double-blind, placebo-controlled, multicenter clinical trial to evaluate Sarepta Therap
- Policy
- Securing Paxlovid's inventory for 120,000 people
- by Lee, Jeong-Hwan Mar 14, 2022 05:50am
- Paxlovid's inventory in Korea is about 120,000 people, it said on the 11th. The response is to the point that there is no shortage of prescriptions for confirmed patients, which has been on the rise recently, and that there is no inventory of Paxlovid at front-line pharmacies or medical sites. More and more patients want Paxlovid due to th
- Policy
- Yoon Seok Yeol's generation
- by Lee, Jeong-Hwan Mar 13, 2022 08:03pm
- Yoon Seok-yeol, the power of the people, was elected in the 20th presidential election, signaling significant changes in the health care and pharmaceutical bio industries as a whole. Some keywords that are drawing attention right now are "promoting remote non-face-to-face treatment" and "the establishment of a pharmaceutical bio-control to
- Policy
- Omicron's fatality rate is at the level of flu
- by Lee, Jeong-Hwan Mar 10, 2022 05:53am
- The quarantine authorities analyzed that if the COVID-19 vaccine is completed up to the third round, the fatality rate of Omicron mutation will be 0.07%, which is similar to that of the seasonal flu fatality rate (0.05 to 0.1%). In particular, the fatality rate for those under the age of 60 who completed the third vaccination was 0%, while
- Policy
- Finding ways to utilize the Patent-approval linkage system
- by Lee, Hye-Kyung Mar 10, 2022 05:53am
- The MFDS plans to prepare a collection of data so that domestic pharmaceutical companies can pioneer the Chinese pharmaceutical market by utilizing the Patent-approval linkage system within the first half of this year. The MFDS recently announced research services for "Overseas the Patent-approval Linkage System Survey and Domestic Impact Ana
- Policy
- The fatality rate of Omicron is low
- by Lee, Jeong-Hwan Mar 8, 2022 06:08am
- The quarantine authorities announced a full-fledged easing of distancing, saying that it is becoming clearer that the COVID-19 Omicron mutation has a lower severity and fatality rate than the delta mutation. From the 5th to the 20th, the 22 o'clock operating hours limit, which will be applied to groups 1, 2, and 3, will be increased by 1 hour
